Supplements
coffee decreases liver disease risk
In plain terms: Is coffee good for your liver?
Strong support Supplements 🔬 Includes disconfirming
Part of: • Coffee
RefutedContestedStrong support
consensus score 0.79
This is one of coffee's strongest health links. Coffee drinkers have substantially lower rates of liver cancer, cirrhosis, and scarring (fibrosis) - often 40-50% lower at higher intakes. It seems to protect against liver-disease progression more than preventing fatty liver in the first place, but the signal is remarkably consistent.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
17 support 0 contradict 1 tested null 3 mixed · 21 sources, 15 independent groups
What the evidence shows
Coffee has an unusually strong and consistent link to better liver health: meta-analyses report substantially lower risk of liver cancer (HCC), cirrhosis, and advanced fibrosis in coffee drinkers, often 40–50% lower at higher intake, with a clear dose-response.
The evidence (25)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Siani M, Bonfiglio C, Bonfrate L, Donghia R, Pastore MN 2026 · Frontiers in nutrition | observational | supports | low | Southern Italy cohort: MASLD odds decreased with increasing daily coffee, greatest benefit at 4-6 cups/day (OR 0.407, 95% CI 0.186-0.893) vs <1 cup/day. |
| Kennedy OJ, Roderick P, Buchanan R, Fallowfield JA, Hayes PC, Parkes J 2017 · BMJ Open | meta-analysis | supports | moderate | SR+meta 18 cohorts (2.27M): +2 cups/d gives 35% lower HCC (RR 0.65); GRADE very low (no RCTs). |
| Kositamongkol C, Kanchanasurakit S, Auttamalang C, Inchai N, Kabkaew T, Kitpark S, Chaiyakunapruk N, Duangjai A, Saokaew S, Phisalprapa P 2021 · Front Pharmacol | meta-analysis | mixed | moderate | Umbrella: no assoc with NAFLD incidence generally; reduced fibrosis in NAFLD patients (OR 0.67). |
| Zhou S, Hu F, Long Z, Huang H, Li D, Chu M, Zhang L 2025 · Food science & nutrition | observational | supports | moderate | Prospective cohort, 147,263 participants, 12.6yr median follow-up: unsweetened coffee showed dose-dependent lower risk of incident GI disease (HR 0.84 at 2-4 cups/day) with a significant additive interaction for cirrhosis specifically. |
| Goh GB, Chow WC, Wang R, Yuan JM, Koh WP 2014 · Hepatology | observational | supports | high | Singapore Chinese (63k): >=2 cups/d nonviral cirrhosis mortality HR 0.34. |
| Liu F, Wang X, Wu G, Chen L, Hu P, Ren H, Hu H 2015 · PLoS One | meta-analysis | supports | moderate | Meta 16 studies: cirrhosis OR 0.61, fibrosis OR 0.73, dose-dependent. |
| Liu W, Xu X, Chang Q, Yang H, Ma Z, Zhang T, Zhao Y, Zhao L, Xia Y 2026 · Nutrition journal | observational | supports | high | UK Biobank, 185,437 participants, median 10.5yr follow-up, 1536 MASLD cases: unsweetened/caffeinated coffee >2.5 servings/day gave HR 0.70 (0.60-0.82) and 0.78 (0.67-0.91) for MASLD; sugar/artificially-sweetened coffee showed no association |
| Park SY, Freedman ND, Haiman CA, Le Marchand L, Wilkens LR, Setiawan VW 2018 · Cancer Epidemiol Biomarkers Prev | observational | supports | high | Multiethnic Cohort (167k): >=4 cups/d liver cancer HR 0.57, consistent across 5 ethnicities. |
| Kim HS, Rezaee-Zavareh MS, Wang Y, Attia AM, Kwak M, Burm S, Celtik D, Legaspi D, Khattab O, Kim N, Mengistu BM, Larios KN, Kim DS, Ayoub W, Kuo A, Martin P, Vipani A, Wang Y, Liangpunsakul S, Li D, Lu SC, Pandol S, Yang JD 2026 · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | observational | supports | high | UK Biobank, 354,957 participants, ≥13yr follow-up: ≥5 cups/day vs none gave HR 0.68 (0.58-0.79) cirrhosis, 0.53 (0.34-0.83) HCC, 0.58 (0.45-0.74) liver mortality; imaging showed lower hepatic fat/iron/fibroinflammation and favorable proteom |
| Vargas-Pozada EE, Ramos-Tovar E, Márquez-Quiroga LV, Ortega-Carballo KJ, Muriel P 2025 · Biochemical pharmacology | observational | supports | moderate | Narrative/mechanistic review: cites epidemiological and clinical evidence that regular coffee consumption reduces risk of liver disease progression to fibrosis, cirrhosis, and HCC, alongside lower liver enzymes and reduced liver-disease mor |
| Di Maso M, Boffetta P, Negri E, La Vecchia C, Bravi F 2021 · Adv Nutr | meta-analysis | mixed | moderate | Only liver endpoint pooled is hepatocellular carcinoma: 'Coffee consumption was also inversely associated with HCC (RR = 0.93; 95% CI: 0.80, 1.08), without reaching statistical significance.' Point estimate sits in the claim's direction but the CI includes the null, hence mixed. The abstract reports only the SHAPE of the dose-response, not its significance: 'The dose-response relation was nonlinear uniquely for CVD' and 'For other outcomes, the risk decreased linearly over the whole coffee consumption range.' Outcomes pooled are CVD, T2D, endometrial cancer, melanoma, nonmelanoma skin cancer and HCC — cirrhosis, fibrosis and NAFLD are not among them. |
| Ebadi M, Ip S, Bhanji RA, Montano-Loza AJ 2021 · Nutrients | meta-analysis | mixed | moderate | Meta: no assoc with NAFLD incidence (RR 0.88 ns) BUT 35% lower significant fibrosis (RR 0.65). |
| Emadi RC, Kamangar F 2025 · Nutrients | observational | mixed | low | Narrative review of coffee and health. It points both ways on the liver: a meta-analysis of 18 studies found substantially lower risk of liver cancer in coffee drinkers, but the authors call the wider link controversial - a recent meta-analysis and umbrella review 'did not find a lower risk of NAFLD among coffee drinkers, but it found a substantially reduced risk of fibrosis among NAFLD patients', and randomized trials showed no overall reduction in the liver enzymes ALT, AST, GGT or ALP. The senior author consults for the National Coffee Association. |
| Yu C, Cao Q, Chen P, Yang S, Deng M, Wang Y, Li L 2016 · Sci Rep | meta-analysis | supports | high | Dose-response meta 20 cohorts: highest vs occasional liver cancer RR 0.55; linear dose-response. |
| Pham K, Kassaw NA, Mulugeta A, Zhou A, Hyppönen E 2025 · Nutrition research reviews | meta-analysis | supports | high | Systematic review of 59 Mendelian randomisation studies (160 disease/biomarker associations): probable evidence for a protective effect of genetically-predicted coffee consumption on hepatocellular carcinoma risk. |
| Bravi F, Tavani A, Bosetti C, Boffetta P, La Vecchia C 2017 · Eur J Cancer Prev | meta-analysis | supports | high | Meta: HCC RR 0.66 and chronic liver disease RR 0.62 in coffee drinkers. |
| Setiawan VW, Wilkens LR, Lu SC, Hernandez BY, Le Marchand L, Henderson BE 2015 · Gastroenterology | observational | supports | high | Multiethnic Cohort (162k): >=4 cups/d HCC RR 0.59; chronic-liver-disease mortality RR 0.29. |
| Geier A, Kabelitz MA, Rau M, Serfert Y, Pathil A, Hofmann WP, von der Ohe M, Ludwig L, Heyne R, Stein K, Berg T, Buggisch P, Demir M, Roeb E, Maasoumy B, Zeuzem S, Wedemeyer H, Schattenberg J 2026 · Zeitschrift fur Gastroenterologie | observational | supports | moderate | German SLD-Registry, 903 MASLD patients: high-risk liver stiffness (≥9.6kPa) less frequent among coffee consumers vs non-consumers (OR 0.58, 95% CI 0.34-0.97, p=0.04) with significant dose-dependency (p<0.003). |
| Whitfield JB, Schwantes-An TH, Darlay R, Aithal GP, Atkinson SR, Bataller R, Botwin G, Chalasani NP, Cordell HJ, Daly AK, Day CP, Eyer F, Foroud T, Gleeson D, Goldman D, Haber PS, Jacquet JM, Liang T, Liangpunsakul S, Masson S, Mathurin P, Moirand R, McQuillin A, Moreno C, Morgan MY, Mueller S, Müllhaupt B, Nagy LE, Nahon P, Nalpas B, Naveau S, Perney P, Pirmohamed M, Seitz HK, Soyka M, Stickel F, Thompson A, Thursz MR, Trépo E, Morgan TR, Seth D, GenomALC Consortium 2021 · J Hepatol | observational | tested-null | moderate | Coffee did NOT improve genetic/clinical risk-score prediction of alcohol-related cirrhosis (null). |
| Chen P, Wang S, Zhang T, Chen EQ 2026 · Public health nutrition | observational | supports | low | NHANES 2013-2018, 8062 adults: coffee consumption inversely associated with NAFLD (OR 0.96, 95% CI 0.94-0.99) after adjustment; 2 cups/day optimal in women. |
| Bravi F, Bosetti C, Tavani A, Gallus S, La Vecchia C 2013 · Clin Gastroenterol Hepatol | meta-analysis | supports | high | Meta 16 studies: any coffee HCC RR 0.60; high intake RR 0.44. |
| Kwapien E, Piszka M, Czarnecki F, Mesyasz M, Owczarska A, Dacyl H, Banach J, Kasprzyk WZ, Luczak JK, Bartkowski J 2025 · Cureus | observational | supports | low | Broad narrative review of coffee's systemic health effects: cites reduced risk of liver cancer and lower incidence of liver fibrosis among the metabolic/chemopreventive benefits of moderate coffee intake. |
| Khalifa R, Al-Naamani K, Elbadry M, Zhang YY, Alswat K, El-Kassas M 2025 · Journal of viral hepatitis | observational | supports | moderate | Narrative review of epidemiological/clinical evidence: regular coffee intake linked to reduced progression to fibrosis, cirrhosis, and HCC across chronic liver diseases, with optimal dose at 3-4 cups/day. |
| Bai K, Cai Q, Jiang Y, Lv L 2016 · Onco Targets Ther | meta-analysis | supports | moderate | Meta 11 studies: HCC pooled OR 0.49. |
| Hayat U, Siddiqui AA, Okut H, Afroz S, Tasleem S, Haris A 2020 · Ann Hepatol | meta-analysis | supports | moderate | Meta 11 studies: NAFLD RR 0.77; lower fibrosis risk. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.